Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes
NCT07606872 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2026-05-26
Summary
This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.
Once classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.
The main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.
The study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Insulin Resistance
- Metabolic Syndrome
Interventions
- BEHAVIORAL
-
Phenotype-Matched Dietary Protocol
A structured dietary plan tailored to the participant's SMS Confirmed Phenotype. Options include low-carbohydrate diet (Pillar A dominant), anti-inflammatory diet (Pillar B dominant), cortisol-regulating diet (Pillar C dominant), prebiotic/probiotic-rich diet (Pillar D dominant), or mitochondrial support diet (Pillar E dominant).
- BEHAVIORAL
-
Structured Progressive Exercise Protocol
A progressive exercise program combining resistance training and aerobic activity, delivered through the diabetesreversal.io platform with instructional videos and weekly progression targets.
- DIETARY_SUPPLEMENT
-
Targeted Nutritional Supplementation
Nutritional supplements selected based on the participant's SMS phenotype and identified deficiencies. May include magnesium, berberine, omega-3 fatty acids, vitamin D, CoQ10, or probiotic formulations depending on the Confirmed Phenotype.
- BEHAVIORAL
-
Structured Intermittent Fasting Protocol
Optional structured intermittent fasting periods with a mandatory 24-hour fasting safety protocol including pre-fast physician consultation, 4-hourly glucose monitoring, defined stop criteria, and carbohydrate availability requirements.
Sponsors & Collaborators
-
Salah Snouda
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-30
- Primary Completion
- 2026-12-31
- Completion
- 2027-03-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
NCT05214573 ·Status: COMPLETED
-
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)
NCT03929679 ·Status: COMPLETED
-
An Integrative Study of the Role of Microbiome, Metabolome, Transcriptome and Chronobiology in the Context of Type 2 Diabetes.
NCT06783218 ·Status: COMPLETED
-
Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
NCT05914857 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Using of SGLt2 Inhibitors in Patients With Type 2 DM
NCT06268977 ·Status: NOT_YET_RECRUITING
-
A Study In Patients With Type 2 Diabetes Mellitus
NCT00256867 ·Status: COMPLETED ·Phase: PHASE3
-
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
NCT04907214 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)
NCT03627039 ·Status: UNKNOWN
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
NCT05972564 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Prospective Observational Study Assessing Treatment and Outcomes of Patients With Prediabetes
NCT01869101 ·Status: UNKNOWN
-
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
NCT06682351 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
NCT02597101 ·Status: COMPLETED ·Phase: PHASE2
-
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
NCT07255807 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
NCT06668753 ·Status: NOT_YET_RECRUITING
-
Type 2 Diabetes and Associated Factors in Mexico
NCT07248891 ·Status: ENROLLING_BY_INVITATION
-
Development of Minimally Invasive Methodology for Diabetyping to Personalise Treatment to Realise Remission and Reversal of Type 2 Diabetes
NCT06125119 ·Status: RECRUITING
-
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
NCT02592421 ·Status: COMPLETED ·Phase: PHASE3
-
THE Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus
NCT07049601 ·Status: COMPLETED ·Phase: NA
-
Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)
NCT02194608 ·Status: COMPLETED ·Phase: NA
-
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
NCT02528019 ·Status: UNKNOWN ·Phase: PHASE4
-
Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
NCT02371187 ·Status: COMPLETED ·Phase: PHASE2
-
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
NCT03878706 ·Status: RECRUITING
-
Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk
NCT00520962 ·Status: COMPLETED
-
SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
NCT05256706 ·Status: COMPLETED ·Phase: NA
-
Novel Classification of Adult-onset Diabetes and Its Association With Common Microvascular Complications in Upper Egypt
NCT04847414 ·Status: UNKNOWN